Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Daiichi Sankyo

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata Meanwhile, Daiichi Sankyo has said it will concentrate on first-line use of quizartinib after being turned down by regulators in Europe and the US, and says it recently completed enrolment ... There are differences between the two drugs, as quizartinib

Seattle Genetics preps filing next year for oral HER2 drug

Seattle Genetics preps filing next year for oral HER2 drug Competition in the HER2 category is heating up though, with a new antibody-drug conjugate from Daiichi Sankyo and AstraZeneca –  trastuzumab deruxtecan – angling for approval in the US in the second

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs Could add to AZ's portfolio of emerging cancer drugs. AstraZeneca and Daiichi have picked up a priority review from the FDA for their breast cancer therapy trastuzumab deruxtecan, setting up ... Analysts’ expectations for sales potential vary,

Leading AstraZeneca’s return to growth in Europe

Leading AstraZeneca’s return to growth in Europe Looking to build its momentum in oncology even further, AstraZeneca recently signed a huge $6.9bn deal with Daiichi-Sankyo to develop and co-market its next-generation challenger to

Astellas’ Xospata scores positive CHMP recommendation

Astellas’ Xospata scores positive CHMP recommendation The positive recommendation puts Astellas even further in the lead in front of Daiichi Sankyo – its candidate for FLT3-positive AML was rejected by the FDA earlier this year following misgivings

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics